Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Changes Name to Oscient

NEW YORK, April 13 (GenomeWeb News) - Genome Therapeutics said today that it has changed its name to Oscient Pharmaceuticals "to better reflect its focus on drug development and commercialization" following its merger with Genesoft Pharmaceuticals in February.

Genome Therapeutics shareholders approved the change to Oscient (pronounced AWE-see-ent) today at the company's annual meeting in Boston. The name change will take effect immediately and the company's stock will continue to trade on Nasdaq under the ticker symbol "GENE."

Oscient's corporate headquarters will remain in Waltham, Mass., with west coast offices in South San Francisco.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.